← All indications
Plasmablastic Lymphoma
Malignant lymphoma composed of large B lymphoid cells which have the immunophenotype of plasma cells and a predilection for the ORAL CAVITY.
Drugs by status
Phase 2 trials (20)
- urea
- prednisone
- doxorubicin
- naltrexone
- nivolumab
- ixazomib
- lentivirus vector ccr5 shrna/trim5alpha/tar decoy-transduced autologous cd34-positive hematopoietic progenitor cells
- vincristine
- carmustine
- cyclophosphamide
- bortezomib
- vorinostat
- varlilumab
- rituximab
- daratumumab
- etoposide
- cytarabine
- melphalan
- dexamethasone
- autologous hematopoietic stem cells
Phase 1 trials (4)
Organizations
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (23)
- Seattle Genetics
- Millennium Pharmaceuticals
- Lederle
- GlaxoSmithKline
- The EMMES Corporation
- AIDS Malignancy Consortium
- Case Western Reserve University
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- Northwestern University
- Rutgers University
- Stanford University
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Michigan
- University of Nebraska
- Mayo Clinic
- University of Chicago
- University of Texas at Houston
- State University of New York, Buffalo
- American Cancer Society, Inc.
Organization Involved with Phase 1 Indications (16)
- Morphotek
- Arno Therapeutics
- University of Pittsburgh
- Cancer and Leukemia Group B (CALGB)
- Johns Hopkins University
- Ohio State University
- University of Rochester
- University of Toronto
- Wake Forest University
- Wayne State University
- University of California, San Diego
- University of Colorado, Denver
- City of Hope National Medical Center
- University of Wisconsin
- Damon Runyon Cancer Research Foundation
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (1)